About the ALPHA3 Clinical Study

The ALPHA3 clinical study will evaluate an investigational CAR T-cell therapy called cemacabtagene ansegedleucel (or “cema-cel,” pronounced “SEM-a-sell”) in patients with B‑cell lymphoma after they have completed their initial (first line) treatment, typically chemotherapy. “Investigational” means that it has not been approved by the FDA at this time. The ALPHA3 clinical study incorporates an investigational diagnostic blood test to determine if patients with DLBCL or a similar type of lymphoma are found to have what is known as minimal residual disease (MRD). Research shows that patients who are MRD negative (MRD-) are unlikely to have their cancer return. However, patients who test MRD+ are considered to be at high risk of their cancer coming back, also known as relapse, and may be eligible to proceed to the next step and continue participating in this clinical study.